104 related articles for article (PubMed ID: 25637407)
1. Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital.
Ayres LR; de Almeida Campos MS; de Oliveira Gozzo T; Martinez EZ; Ungari AQ; de Andrade JM; Pereira LR
Int J Clin Pharm; 2015 Apr; 37(2):365-72. PubMed ID: 25637407
[TBL] [Abstract][Full Text] [Related]
2. Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience.
Staropoli N; Scionti F; Farenza V; Falcone F; Luciano F; Renne M; Di Martino MT; Ciliberto D; Tedesco L; Crispino A; Labanca C; Cucè M; Esposito S; Agapito G; Cannataro M; Tassone P; Tagliaferri P; Arbitrio M
Biomed Pharmacother; 2024 May; 174():116478. PubMed ID: 38547766
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer.
Sardesai S; Sukumar J; Kassem M; Palettas M; Stephens J; Morgan E; Addison D; Baliga R; Stover DG; VanDeusen J; Williams N; Cherian M; Lustberg M; Wesolowski R; Ramaswamy B
Cardiooncology; 2020 Nov; 6(1):26. PubMed ID: 33292843
[TBL] [Abstract][Full Text] [Related]
4. Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA).
Reuvekamp EJ; Bulten BF; Nieuwenhuis AA; Meekes MR; de Haan AF; Tol J; Maas AH; Elias-Smale SE; de Geus-Oei LF
J Nucl Cardiol; 2016 Aug; 23(4):824-32. PubMed ID: 26048264
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario.
Shrivastva S; Bala SC; Chennamaneni R; Konatam ML; Pydi VR; Prasad KS; Gundeti S
South Asian J Cancer; 2023 Jul; 12(3):233-237. PubMed ID: 38047057
[TBL] [Abstract][Full Text] [Related]
6. Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer.
de la Brassinne Bonardeaux O; Born B; Moonen M; Lancellotti P
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959174
[TBL] [Abstract][Full Text] [Related]
7. HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients.
Blancas I; Linares-Rodríguez M; Martín-Bravo C; Gómez-Peña C; Rodríguez-Serrano F
Clin Transl Oncol; 2024 May; ():. PubMed ID: 38771533
[TBL] [Abstract][Full Text] [Related]
8. Assessing Adherence to Cardiac Monitoring Guidelines in Trastuzumab-Treated Breast Cancer Patients: Insights From a Tertiary Hospital.
Alhuthali A; Alshammari A; Saleh K; Jaffal M; Bajnaid E; Almutairi MS; Almuylibi Z; Alghanmi A; Alnuhait M
Cureus; 2023 Nov; 15(11):e48832. PubMed ID: 38106693
[TBL] [Abstract][Full Text] [Related]
9. Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy.
Yao RJR; Gibson J; Simmons C; Davis MK
Cardiooncology; 2021 Mar; 7(1):12. PubMed ID: 33766148
[TBL] [Abstract][Full Text] [Related]
10. Acetylcholinesterase inhibition protects against trastuzumab-induced cardiotoxicity through reducing multiple programmed cell death pathways.
Khuanjing T; Maneechote C; Ongnok B; Prathumsap N; Arinno A; Chunchai T; Arunsak B; Chattipakorn SC; Chattipakorn N
Mol Med; 2023 Sep; 29(1):123. PubMed ID: 37691124
[TBL] [Abstract][Full Text] [Related]
11. Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies.
Agunbiade TA; Zaghlol RY; Barac A
Methodist Debakey Cardiovasc J; 2019; 15(4):250-257. PubMed ID: 31988685
[TBL] [Abstract][Full Text] [Related]
12. Preventive effect of dexamethasone premedication on the development of infusion-related reaction in breast cancer patients receiving trastuzumab.
Goto E; Hata T; Nishihara M; Neo M; Iwamoto M; Kimura K; Goto M; Rikitake Y
Br J Clin Pharmacol; 2023 Jul; 89(7):2102-2112. PubMed ID: 36709967
[TBL] [Abstract][Full Text] [Related]
13. HER2-Targeted Therapy-From Pathophysiology to Clinical Manifestation: A Narrative Review.
Slavcheva SE; Angelov A
J Cardiovasc Dev Dis; 2023 Dec; 10(12):. PubMed ID: 38132657
[TBL] [Abstract][Full Text] [Related]
14. What Powers Trastuzumab's Cardiotoxicity? Decoding Mitochondrial-Related Gene Expression Through Integrative Review and Meta-Analysis in Cardiomyocytes.
Rodrigues KDS; Caetano DSL; Cavalcante JV; Dalmolin R; Ziegelmann PK; Andrades M
OMICS; 2024 Mar; 28(3):103-110. PubMed ID: 38466948
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity related to long-term trastuzumab therapy in metastatic breast cancer: the potential role of treatment duration and cardiac risk factors.
Pistilli B; Marcellusi A; Latini L; Accardi R; Ferretti B; Benedetti G
Breast J; 2015; 21(3):318-21. PubMed ID: 25790346
[No Abstract] [Full Text] [Related]
16. Breast cancer therapy and cardiovascular risk: focus on trastuzumab.
Sandoo A; Kitas GD; Carmichael AR
Vasc Health Risk Manag; 2015; 11():223-8. PubMed ID: 25897242
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.
Yamshiro H; Iwata H; Masuda N; Yamamoto N; Nishimura R; Ohtani S; Sato N; Takahashi M; Kamio T; Yamazaki K; Saito T; Kato M; Lee T; Ohno S; Kuroi K; Takano T; Takada M; Yasuno S; Morita S; Toi M
Int J Clin Oncol; 2015 Aug; 20(4):709-22. PubMed ID: 25666483
[TBL] [Abstract][Full Text] [Related]
18. Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer.
Pernin V; Belin L; Cottu P; Bontemps P; Lemanski C; De La Lande B; Baumann P; Missohou F; Levy C; Peignaux K; Reynaud-Bougnoux A; Denis F; Gobillion A; Bollet M; Vago NA; Dendale R; Campana F; Fourquet A; Kirova YM
Br J Radiol; 2015 Apr; 88(1048):20140800. PubMed ID: 25645108
[TBL] [Abstract][Full Text] [Related]
19. Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients.
Mustacchi G; Puglisi F; Molino AM; Crivellari D; Ghiotto C; Ferro A; Brunello A; Saracchini S; Turazza M; Cretella E; Iop A; Malagoli M; Stefani M
Future Oncol; 2015; 11(10):1493-500. PubMed ID: 25708426
[TBL] [Abstract][Full Text] [Related]
20. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
